Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07076342 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Role of mGluR5 in CBT-I

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Jun 2030 to Mar 31, 2030v4
  2. Trial status: Enrolling by Invitation to Recruiting
    • Start date changed from estimate of Jul 2025 to Aug 1, 2025
    • Site details revised
    v3
  3. Study description expanded, about 2 wordsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is mechanistic clinical trial that evaluates the role of one of the glutamate receptors (mGluR5) in cognitive behavioral therapy for insomnia (CBT-I) as a common pathway in improving sleep and depression.
Trial Details
NCT Number NCT07076342
Lead Sponsor Stony Brook University
Collaborators: National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Conditions
(from sponsor)		 Major Depressive Disorder (MDD)
Related terms Major Depressive Disorder, Sleep Initiation and Maintenance Disorders
Enrollment 42 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov